Marshall Wace
LXRX icon

Marshall Wace’s Lexicon Pharmaceuticals LXRX Stock Holding History

Marshall Wace’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,376,304
Closed -$3.71M – 3489
2026
Q1 		$3.71M Buy
2,376,304
+1,113,937
+88% +$1.62M ﹤0.01% 1451
2025
Q4 		$1.45M Buy
+1,262,367
New +$1.73M ﹤0.01% 1752
2024
Q4 		– Sell
-574,150
Closed -$901K – 2829
2024
Q3 		$901K Sell
574,150
-616,298
-52% -$1.1M ﹤0.01% 1689
2024
Q2 		$2M Buy
1,190,448
+691,276
+138% +$1.24M ﹤0.01% 1369
2024
Q1 		$1.2M Buy
+499,172
New +$1.07M ﹤0.01% 1581
2023
Q3 		– Sell
-125,287
Closed -$287K – 2483
2023
Q2 		$287K Buy
+125,287
New +$333K ﹤0.01% 2155
2020
Q4 		– Sell
-281,647
Closed -$406K – 2057
2020
Q3 		$406K Sell
281,647
-654,944
-70% -$1.17M ﹤0.01% 1288
2020
Q2 		$1.87M Sell
936,591
-409,019
-30% -$801K 0.01% 816
2020
Q1 		$2.62M Buy
1,345,610
+494,682
+58% +$1.47M 0.03% 540
2019
Q4 		$3.53M Buy
+850,928
New +$3.28M 0.02% 646
2019
Q1 		– Sell
-264,139
Closed -$1.75M – 1917
2018
Q4 		$1.75M Buy
264,139
+229,876
+671% +$1.86M 0.02% 763
2018
Q3 		$366K Sell
34,263
-616,555
-95% -$7.06M ﹤0.01% 990
2018
Q2 		$7.81M Sell
650,818
-85,727
-12% -$877K 0.12% 211
2018
Q1 		$6.31M Buy
+736,545
New +$6.81M 0.26% 92
2015
Q3 		– Sell
-12,945
Closed -$104K – 1007
2015
Q2 		$104K Sell
12,945
-63,724
-83% -$468K ﹤0.01% 855
2015
Q1 		$507K Buy
+76,669
New +$524K 0.01% 668

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace's LXRX Position: Q2 2026 in Review

Marshall Wace sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 2,376,304 shares — an estimated $3.71M sold.

Marshall Wace first reported a position in LXRX in Q1 2015 and held it in 16 quarters. The position peaked at $7.81M in Q2 2018. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Marshall Wace reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 2,376,304 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $3.71M.
  • Marshall Wace first reported a position in Lexicon Pharmaceuticals in Q1 2015 and held it in 16 quarters.
  • Marshall Wace's Lexicon Pharmaceuticals position peaked at $7.81M in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.